Labcorp will deploy Roche’s cobas Mass Spec platform in its US labs, marking the first commercial rollout of this system to streamline complex diagnostic testing workflows.
Labcorp has entered into a commercial agreement with Roche to implement the cobas Mass Spec solution, marking the first US commercial laboratory deployment of the fully automated mass spectrometry platform, according to a release from the company.
The collaboration introduces automated mass spectrometry workflows into routine clinical practice, targeting faster turnaround times and improved accuracy for complex diagnostic testing. The platform is designed to eliminate manual processes that have historically limited mass spectrometry use in routine clinical laboratories.
“Labcorp is committed to advancing diagnostic science through transformative technologies,” says Marcia Eisenberg, PhD, Labcorp’s chief scientific officer, in a release. “Integrating Roche’s automated mass spectrometry solution will enable us to deliver greater accuracy and efficiency for critical tests that guide treatment decisions and improve patient outcomes.”
Targeting Complex Diagnostic Applications
Mass spectrometry identifies and measures molecules based on their weight and electrical charge, making it essential for complex testing including steroid hormone analysis, vitamin D measurement, and therapeutic drug monitoring. The technique’s selectivity, sensitivity, and accuracy are particularly valuable for tests where small variations can impact treatment decisions.
The cobas Mass Spec solution automates the workflow from sample preparation to result interpretation. The platform features a fully automated workflow designed to reduce complexity and turnaround times, with approximately 60 assays planned for introduction over time. The system is designed for future integration with clinical chemistry and immunochemistry analyzers.
“This collaboration reflects our shared vision to make advanced diagnostics widely accessible,” says Brad Moore, president and CEO of Roche Diagnostics North America, in a release. “Together, we are setting a new benchmark for accuracy, reliability, and efficiency in patient care.”
Phased Implementation Timeline
The cobas Mass Spec solution will be deployed initially at Labcorp’s Burlington, North Carolina, laboratory, with launch expected in the first quarter of 2026. Implementation will then expand to additional Labcorp locations following the initial deployment.
The agreement builds on an existing collaboration between Labcorp and Roche, supporting Labcorp’s diagnostics and biopharma laboratory services business segments. The partnership aims to address limitations that have historically restricted mass spectrometry to specialized laboratories requiring dedicated expertise and manual processes.
Photo caption: Roche’s cobas 6800/8800 systems
File photo / Roche
